Syngene International share price falls 2.02%; stock among top losers on Nifty Midcap 150

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Shares of Syngene International declined by 2.02% to Rs 669.25 in Wednesday's session, emerging as one of the top losers on the Nifty Midcap 150. This movement reflects a shift in investor sentiment, with the stock experiencing selling pressure.

Financial Snapshot

Syngene International's financial performance reveals the following trends:

Consolidated Quarterly Results:

The company's consolidated quarterly revenue and net profit figures show fluctuations over the recent quarters. Revenue increased from Rs 789.70 Crore in June 2024 to Rs 1,018.00 Crore in March 2025, before decreasing to Rs 874.50 Crore in June 2025. Net profit followed a similar trend, starting at Rs 75.70 Crore in June 2024, peaking at Rs 183.30 Crore in March 2025, and then falling to Rs 86.70 Crore in June 2025.

The annual financial performance indicates consistent growth in revenue from Rs 2,184.30 Crore in 2021 to Rs 3,642.40 Crore in 2025. However, net profit showed variability, with a decrease from Rs 510.00 Crore in 2024 to Rs 496.20 Crore in 2025. Earnings per share (EPS) also experienced fluctuations, peaking at Rs 12.71 in 2024 and slightly decreasing to Rs 12.35 in 2025.

The consolidated annual income statement reveals that sales increased from Rs 2,184 Crore in March 2021 to Rs 3,642 Crore in March 2025. Total income also rose from Rs 2,248 Crore to Rs 3,714 Crore during the same period. Total expenditure increased from Rs 1,752 Crore in March 2021 to Rs 3,001 Crore in March 2025. Consequently, EBIT increased from Rs 496 Crore to Rs 713 Crore. Net profit showed a fluctuating trend, with Rs 404 Crore in March 2021, increasing to Rs 510 Crore in March 2024, and then decreasing to Rs 496 Crore in March 2025.

The consolidated quarterly income statement indicates that sales increased from Rs 789 Crore in June 2024 to Rs 1,018 Crore in March 2025, before decreasing to Rs 874 Crore in June 2025. Total income followed a similar trend, increasing from Rs 807 Crore in June 2024 to Rs 1,036 Crore in March 2025, and then decreasing to Rs 892 Crore in June 2025. Net profit increased from Rs 75 Crore in June 2024 to Rs 183 Crore in March 2025, and then decreased to Rs 86 Crore in June 2025.

The consolidated cash flow statement reveals that cash flow from operating activities has been consistently positive, with Rs 1,167 Crore in March 2025. Cash flow from investing activities has been negative, with -Rs 744 Crore in March 2025, indicating investments in assets. Cash flow from financing activities has also been negative, with -Rs 141 Crore in March 2025, suggesting debt repayments and dividend payouts. The net cash flow in March 2025 stood at Rs 281 Crore.

The consolidated balance sheet shows that total assets increased from Rs 4,883 Crore in March 2021 to Rs 6,795 Crore in March 2025. Fixed assets also increased from Rs 2,438 Crore to Rs 4,067 Crore during the same period. The company's share capital has remained relatively stable at around Rs 400 Crore. Reserves and surplus have increased from Rs 2,421 Crore in March 2021 to Rs 4,324 Crore in March 2025.

Key financial ratios for Syngene International indicate a P/E ratio of 58.80 and a P/B ratio of 6.18 as of March 2025. The company reported a debt-to-equity ratio of 0.03 as of the year-ending March 2025.

Syngene International announced several analyst/investor meetings in early August 2025, with one meeting being cancelled.

The company announced a final dividend of Rs 1.25 per share (12.5%) with an effective date of June 27, 2025.

Syngene International had a bonus issue with a ratio of 1:1, with exbonus date as June 11, 2019.

With the stock's last traded price at Rs 669.25, Syngene International experienced a notable decline in today's session, reflecting broader market dynamics and investor reactions to the company's financial health and corporate actions.